S everal large registries have demonstrated the high prevalence of chronic kidney disease (CKD) among patients with acute myocardial infarction (MI), [1] [2] [3] the inverse correlation between worsening renal function and use of evidence-based therapies, 1, [4] [5] [6] and poor short-and long-term outcomes among these patients. [7] [8] [9] [10] In addition to greater comorbidities and baseline risk 11 and challenges in establishing a timely diagnosis of MI because of atypical presentation characteristics, 2,12 lower use of guidelinerecommended therapies has been postulated as a reason for worse outcomes among these patients. 3 Over the past decade, several medical [13] [14] [15] and interventional strategies 16 have demonstrated improvements in outcomes after MI; however, patients with renal dysfunction have typically been excluded from these studies. 17 Thus, the application of this evidence base to patients with renal disease, particularly those with end-stage renal disease (ESRD) treated with dialysis, may not be automatically extrapolated. A study performed by the Cardiovascular Special Studies Center of the US Renal Data System showed a decrease in mortality following ST-segment-elevation MI (STEMI) in dialysis patients between 1993 and 2008 but not among non-STEMI (NSTEMI) patients. 18 This report, however, was limited by the precision needed to reliably distinguish STEMI from NSTEMI and by data on the use of concomitant evidence-based therapies. Trends in the use of these evidence-based therapies and in outcomes among patients with CKD in the contemporary era are unknown. Therefore, in this study, we utilized the NCDR (National Cardiovascular Data Registry) ACTION Registry (Acute Coronary Treatment and Intervention Outcomes Network Registry)-Get With the Guidelines (ACTION Registry-GWTG) database to examine temporal trends in the use of evidencebased therapies and in-hospital clinical outcomes of MI patients with CKD over the past decade. We specifically sought to determine whether the use of guideline-recommended inhospital and discharge therapies and in-hospital clinical outcomes differed over time by MI type (STEMI versus NSTEMI) and by presence and degree of renal dysfunction.
Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Data Source and Analysis Population
All patients enrolled with MI in the NCDR ACTION Registry-GWTG from January 1, 2007, to December 31, 2015 , were included in the initial study population (n=1 077 521 from 1177 hospitals). The NCDR ACTION Registry-GWTG serves as a hospital data collection and evaluation mechanism for MI patients in the United States and has been described previously. 19 All participating hospitals were required to comply with local regulatory and privacy guidelines and, if required, to secure institutional review board approval. Because data were used primarily at the local site for quality improvement, sites were granted a waiver of informed consent under the common rule. Baseline demographics, presentation characteristics, in-hospital investigations, treatments, and outcomes were compared among the 3 groups, separately for STEMI and NSTEMI cohorts. In particular, frequency of primary PCI among eligible candidates, timeliness of reperfusion therapy (door-to-balloon [D2B] time), and frequency of medical therapy within 24 hours of presentation and at hospital discharge were determined among STEMI patients. Among NSTEMI patients, the frequency of medical therapy within 24 hours of presentation and at hospital discharge and the frequency of cardiac catheterization and revascularization in the hospital were determined. In-hospital clinical outcomes examined included mortality, major bleeding, 20 and moderate to severe acute kidney injury (AKI), defined as a ≥0.5-mg/dL change between peak and initial absolute creatinine values. Finally, we determined the association between time period and in-hospital treatments, as well as outcomes stratified by presence and degree of CKD. Logistic regression modeling was used to evaluate the association between calendar year (binary variable: 1=patients discharged in
Clinical Perspective
What Is New?
• Uptake of evidence-based medical and invasive therapies has increased over the past decade among myocardial infarction patients with chronic kidney disease, particularly dialysis patients.
• In-hospital mortality has improved among non-ST-segmentelevation myocardial infarction patients with chronic kidney disease, but not ST-elevation-myocardial infarction patients with chronic kidney disease.
What Are the Clinical Implications?
• These trends likely reflect a combination of accumulation of evidence supporting the benefit of these therapies in patients with chronic kidney disease and increased awareness and less therapeutic nihilism on the part of the practitioner.
• Although encouraging, persistent high residual early mortality rates demonstrate opportunities for further improvement in care of this high-risk population. 
Clinical outcomes
In-hospital outcomes in STEMI patients are shown in Table 3 . Compared with STEMI patients with preserved renal function, in-hospital mortality was %5-fold higher among patients with moderate to severe CKD not requiring dialysis and 7-fold higher among ESRD patients requiring dialysis. Major bleeding was also significantly higher among patients with CKD, particularly among ESRD patients requiring dialysis. Moderate to severe AKI occurred in 16% of patients with moderate to severe CKD and 4.6% of patients with preserved renal function.
In 
NSTEMI Cohort
Among 506 876 patients with NSTEMI, 17 104 (3.4%) had ESRD requiring dialysis, 174 543 (34.4%) had moderate to severe CKD but did not require dialysis, and 315, 229 (62.2%) had preserved renal function. NSTEMI patients with CKD had lower body weight, more comorbidities, and higher risk features on presentation ( Table 4 
Medical and invasive therapy use
Use of aspirin, P2Y 12 receptor inhibitors, b-blockers, angiotensin-converting enzyme inhibitors, and statins within 24 hours and anticoagulation in the hospital were lower among NSTEMI patients with CKD, particularly among ESRD patients requiring dialysis (Table 5 ). Similar to the STEMI cohort, coronary angiography was performed less frequently among NSTEMI patients with CKD; however, unlike the STEMI population, among patients undergoing coronary angiography, PCI and coronary artery bypass grafting was performed less frequently among patients with CKD. At hospital discharge, use of P2Y 12 receptor inhibitors, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and statins was also lower among NSTEMI patients with CKD.
Early in-hospital and discharge use of aspirin increased from 2007-2008 to 2014-2015, regardless of the presence 
Clinical outcomes
Compared with NSTEMI patients with preserved renal function, in-hospital mortality was %4-fold higher among patients with moderate to severe CKD and 5-fold higher among ESRD patients requiring dialysis ( 
Discussion
In this largest, contemporary evaluation of in-hospital treatment and outcomes of MI patients with CKD in the United States, several important observations emerge. First, CKD ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; DES, drug-eluting stent; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention. *Among patients undergoing angiography.
angiography and PCI also increased over time among NSTEMI patients with CKD; however, unlike STEMI patients, in addition to in-hospital bleeding, in-hospital mortality was lower over time in NSTEMI patients regardless of presence or degree of CKD. Consistent with prior reports, 1,9,21-24 CKD remains prevalent among patients with MI and is associated with a graded increase in adverse in-hospital outcomes, both mortality and bleeding, with worsening kidney function. Despite this increased risk for adverse outcomes, compared with patients with preserved renal function, CKD patients receive fewer evidence-based therapies. Several reasons have been postulated for this apparent undertreatment of this high-risk population. Patients with CKD, particularly those requiring renal replacement therapy, are typically excluded from clinical trials, and evidence pertaining to improved outcomes with standard evidence-based therapies for MI have been scarce in these patients. Treatment may be discouraged further by the potential for excess toxicities with certain therapies and a high prevalence of comorbidities that may be perceived as contraindications. However, recent studies suggest that, at least among carefully selected patients, certain treatment benefits appear to outweigh the risks. Data from the SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) registry showed that a 1-year mortality benefit of early revascularization over medical therapy was seen in NSTEMI patients with estimated GFR >30 mL/min, with no benefit seen in patients with estimated GFR <30 mL/min. 5 The benefit of early revascularization on the composite end point of death, MI, and revascularization in patients with creatinine clearance of 30 to 60 mL/min was also noted in a subgroup analysis of the TACTICS-TIMI 18 (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction 18) trial.
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Although contrast-induced AKI is important, its risk needs to be balanced against the marked cardiovascular morbidity and mortality of CKD patients. A retrospective study of >33 000 patients with MI showed that the overall incidence of AKI declined from 26.6% in 2000 to 19.7% in 2008 despite the aging population and rising prevalence of risk factors for acute renal failure, including CKD. 26 This decline in AKI has been postulated to be caused by improved efforts to prevent contrast-induced AKI. Aspirin and b-blockers after MI have been shown to improve outcomes in patients with underlying kidney disease. 3, 27 In a meta-analysis of 27 139 patients with CKD who participated in 50 randomized trials of antiplatelet agents (mostly aspirin), antiplatelet therapy significantly reduced the incidence of fatal or nonfatal MI compared with either placebo or no therapy. Antiplatelet therapy had no effect on mortality or stroke, and increased rates of major bleeding. 28 Unlike NSTEMI, the proportion of STEMI patients with ESRD on dialysis remained constant over the past decade, likely because establishing a diagnosis relies on specific ECG criteria rather than simply on biomarker criteria. Increased use of P2Y 12 receptor inhibitors, coronary angiography, and primary PCI and achievement of D2B times within guideline recommendations among STEMI patients with CKD over the past decade have paralleled STEMI patients without CKD; however, despite this increase in use of invasive and medical therapies, there was no improvement in-hospital mortality. Our observations are similar to findings from the CathPCI registry â , in which, despite significant reductions in D2B time from 2005 to 2009, no reduction in in-hospital mortality was observed among STEMI patients undergoing primary PCI. 35 However, they contrast with data from the US Renal Data System database, in which in-hospital and 2-year cumulative probability of mortality decreased among STEMI dialysis patients between 1993 and 2008. 18 This absence of improvement in in-hospital mortality is not explained by temporal trends in underlying comorbidity, as the proportion of STEMI patients with CKD remained constant over time, as did the patient demographics and features on presentation in the overall cohort and in each group stratified by presence and degree of CKD. Possible explanations include reductions in D2B time that are too small to reduce infarct size, initiation of treatment that is too late, or follow-up that is too short to show improvement in survival. 36 In-hospital mortality after STEMI continues to remain extremely high at %1 in 5 ESRD patients on dialysis and 1 in 7 patients with CKD without dialysis, highlighting the need for additional measures to improve outcomes in this very high-risk population.
Limitations
The data source lacks precision regarding contraindications and reasons for not using individual medications and procedures. Ticagrelor and prasugrel were not available in [2007] [2008] . Only short-term in-hospital outcomes were evaluated. Whether increased angiography and faster reperfusion, greater use of drug-eluting stents and evidence-based medications, and lower rates of AKI and in-hospital bleeding translate into a longer term survival benefit for patients with CKD was not evaluated in this study. Data were extracted from hospitals with different creatinine assays and standards, and no standard central determination of kidney function was performed. The initial creatinine value is assumed to be at steady state, that is, representing chronic kidney function, not AKI. In addition, information on albuminuria and proteinuria was not available.
Conclusions
A progressive increase in uptake of evidence-based medical and invasive therapies has occurred over the past decade among MI patients with CKD, particularly ESRD patients on dialysis. These trends likely reflect a combination of accumulation of evidence supporting the benefit of these therapies in patients with CKD and increased awareness and less therapeutic nihilism on the part of practitioners. Despite increased uptake of these therapies, improvement of inhospital mortality over time was observed only among NSTEMI patients, not STEMI patients. Although encouraging, persistent high residual early mortality rates demonstrate opportunities for further improvement of care for this high-risk population.
